What's Happening?
Eli Lilly and Company has acquired Curevo Vaccine, a move that highlights the significance of the SLA-SE adjuvant technology developed by the Access to Advanced Health Institute (AAHI). Curevo's lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit
vaccine designed to prevent shingles (herpes zoster) and incorporates AAHI's proprietary SLA-SE adjuvant. This acquisition underscores the growing recognition of next-generation adjuvants that offer improved tolerability and robust immune responses. AAHI, a Seattle-based nonprofit biotech organization, focuses on developing vaccines and technologies for global health. The institute retains the rights to license and develop the SLA-SE adjuvant for other uses, including a range of infectious diseases and cancer vaccines.
Why It's Important?
The acquisition of Curevo by Eli Lilly is significant as it brings attention to the advancements in vaccine adjuvant technology, particularly the SLA-SE adjuvant. This technology is designed to elicit strong T-cell immunity with a favorable safety profile, which is crucial for developing effective vaccines with minimal side effects. The deal not only enhances Eli Lilly's vaccine portfolio but also positions AAHI's technology to reach a broader audience through Lilly's development and commercial capabilities. This could lead to more effective vaccines for various infectious diseases, potentially improving public health outcomes and reducing the burden of diseases like shingles.
What's Next?
With the acquisition, Eli Lilly is expected to advance the development and commercialization of the shingles vaccine, leveraging its global reach and resources. AAHI will continue to explore licensing opportunities for the SLA-SE adjuvant in other vaccine fields, potentially expanding its application to other infectious diseases and cancer vaccines. The collaboration between AAHI and Eli Lilly could lead to further innovations in vaccine technology, benefiting public health initiatives worldwide.
